Advertisement
Advertisement
U.S. markets open in 5 hours 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Microba Life Sciences Limited (MAP.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.2000-0.0250 (-11.11%)
At close: 04:10PM AEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2250
Open0.2300
Bid0.2000 x N/A
Ask0.2200 x N/A
Day's Range0.2000 - 0.2400
52 Week Range0.2000 - 0.4500
Volume607,493
Avg. Volume501,433
Market Cap54.872M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MAP.AX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Microba Life Sciences Signs Partnership With Nib-Backed Midnight Health

      BRISBANE, Australia, May 26, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") has signed a strategic partnership agreement ("Agreement") with nib Holdings Limited (ASX: NHF) backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market.

    • Business Wire

      Microba Accelerates Cancer Program With New Leads

      BRISBANE, Australia, May 05, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected. This will enable preclinical animal studies to be brought forward to the end of calendar year 2022 which is approximately 12 months ahead of schedule.

    • Business Wire

      Microba Appoints Therapeutics Head

      BRISBANE, Australia, April 06, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce Professor Trent Munro will be joining the company as Senior Vice President of Therapeutics. Professor Munro has over 25 years’ research and development experience, including with multinational biopharmaceutical company Amgen.

    Advertisement
    Advertisement